Brown: Risk Weighti...
Health Care: Drugs
Pharmacyclics Incorporated (PCYC: NASDAQ)
$84.89 0.97 | 1.16%
05/17/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 83.92 |
| 52 Week High | 95.85 |
| 52 Week Low | 28.77 |
| Avg. Daily Vol. (Mil) | 0.81 |
| Beta (3 year) | 0.93 |
| Share Related Items | |
| Mkt Cap (Mil) | 6,107.95 |
| Shares Out (Mil) | 72.78 |
| Float (Mil) | 39.76 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 11.00 |
| Current Ratio | 11.20 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | 72.30 |
| Price/Sales | 37.08 |
| Price/Book | 13.97 |
| Price/Cash Flow | 59.40 |
| Per Share Data | |
| Earnings | 0.17 |
| Sales | 2.26 |
| Book Value | 6.01 |
| Cash Flow | 1.41 |
| Business Summary | |
|---|---|
| Pharmacyclics, Inc., is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. | |
| General Information | |
| 995 East Arques Avenue
Sunnyvale, CA 94085-4521 |
|
| www.pcyc.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 150 | |
| CEO: Robert W. Duggan | |
| Short Interest | |
| Current Month (Mil) | 2.48 |
| Previous Month (Mil) | 2.69 |
| Short Interest Ratio (Days) | 3.60 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | 0.00 |
| Return on Investments | n.a. |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 14.60 |
Portfolios with PCYC
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
- UserGFNN Stockdiagnostics 28
- UserGFNN Stockdiagnostics 20
- ContributorStocks Rising On Unusual Vo...
- ContributorHot Biotech Stocks Traded b...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- Contributor10 Best-Performing Stocks i...
- ContributorStocks At New 52-Week Highs...
Latest PCYC Headlines from TheStreet
- ASCO '13 Preview: Roche's Next-Gen Rituxan Steps Up 05.15.13 | 06:05 pm
- ASCO '13 Preview: Gilead's Big Cancer Debut 05.15.13 | 06:05 pm
- 10 ASCO '13 Abstracts You Can Read Right Now 05.15.13 | 06:05 pm
- Pharmacyclics Rises On Unusually High Volume (PCYC) 05.13.13 | 03:05 pm
- 3 Biotech Stocks Spiking With Big Volume 05.13.13 | 02:05 pm
- Pharmacyclics Incorporated (PCYC): Today's Featured Drugs Winner 04.22.13 | 05:04 pm
- Pharmacyclics Incorporated (PCYC): Drugs' Featured Daily Laggard 04.09.13 | 05:04 pm
- TheStreet Ratings Top 10 Rating Changes 04.08.13 | 09:04 am
- Pharmacyclics Incorporated Stock Downgraded (PCYC) 04.05.13 | 05:04 am
- Pharmacyclics Incorporated (PCYC): Today's Featured Drugs Laggard 03.19.13 | 05:03 pm
Press Releases for PCYC
- Pharmacyclics Announces Date Of Financial Results For Three Months Ended March 31, 2013 And Conference Call - PR Newswire 04.24.13 | 04:04 pm
- Pharmacyclics Completes Enrollment Of First Phase III Ibrutinib CLL Study - RESONATEâ¿¢ And Announces Completion Of Enrollment Of Phase II Ibrutinib MCL Study - SPARK - PR Newswire 04.18.13 | 04:04 pm
- Pharmacyclics Triggers Fourth Milestone Payment For Enrollment Of 5th Patient In Frontline Phase III CLL Study - PR Newswire 04.11.13 | 06:04 am
- Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid And Sustainable Disease Control Irrespective Of Age Or High Risk Prognostic Factor - PR Newswire 04.08.13 | 01:04 pm
- Pharmacyclics Announces Third Breakthrough Therapy Designation For Ibrutinib From The U.S. Food And Drug Administration - PR Newswire 04.08.13 | 06:04 am
- Pharmacyclics, Inc. Prices Public Offering Of Common Stock - PR Newswire 03.08.13 | 08:03 am
- Pharmacyclics, Inc. Announces Proposed Public Offering Of Common Stock - PR Newswire 03.07.13 | 04:03 pm
- Pharmacyclics First To Announce Breakthrough Therapy Designation In Oncology From The U.S. Food And Drug Administration - PR Newswire 02.12.13 | 07:02 pm
- Pharmacyclics Announces Date Of Financial Results For Three And Six Months Ended December 31, 2012 And Conference Call - PR Newswire 02.07.13 | 04:02 pm
- Pharmacyclics® Announces Updated Results For BTK Inhibitor Ibrutinib (PCI-32765) At American Society Of Hematology (ASH) Annual Meeting - PR Newswire 12.11.12 | 04:12 pm
Partner Headlines for PCYC
- Moves in Smaller Health Care Stocks (ANAC, HALO, PBYI, QCOR) - Benzinga 03.23.13 | 11:03 am
- Regeneron Pharmaceuticals Inc (REGN): Today's Most Compelling Buy - NASDAQ 03.14.13 | 04:03 pm
- Pharmacyclics Is Ripe For A Major Correction - Seeking Alpha 02.16.13 | 06:02 am
- UPDATE: Dawson James Initiates Pharmacyclics at Market Outperform on Ibrutinib Confidence - Benzinga 12.07.12 | 09:12 am
- Celgene, Regeneron Pharmaceutical Lead Biomed Group - Investor's Business Daily 11.30.12 | 05:11 pm
- Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX) - Benzinga 11.12.12 | 01:11 pm
- Benzinga's Top Initiations - Benzinga 11.01.12 | 09:11 am
- The Breakthrough At Northwest Biotherapeutics - Seeking Alpha 10.18.12 | 09:10 am
- Short Interest in Biotech Firms Resumes (BIIB, GILD, ILMN, REGN) - Benzinga 09.26.12 | 01:09 pm
- Pharmacyclics Earns Milestone - Analyst Blog - NASDAQ 08.24.12 | 07:08 pm
